{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:51Z","timestamp":1790352531940,"version":"4.1.0"},"reference-count":17,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Zhongshan Hospital Clinical Research Program","award":["ZSLCYJ202310"],"award-info":[{"award-number":["ZSLCYJ202310"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is the most common endocrine disorder that affects reproductive-aged individuals. Our previous single-arm pilot trial showed that dihydroartemisinin (DHA) normalised menstrual cycles, ameliorated hyperandrogenaemia and reduced antral follicles in individuals with PCOS. However, no comparative evidence confirms the efficacy of DHA in individuals with PCOS when compared with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a multi-centre randomised, double-blinded, placebo-controlled trial of individuals with PCOS who have irregular menstrual cycles and hyperandrogenism, with or without polycystic ovary morphology. A total of 150 participants will be randomised in a 1:1 ratio to receive oral tablets of 40\u2009mg DHA three times per day or placebo for 90 days. The primary outcome is the return of regular menstrual cycles within 6 months after treatment initiation, with antral follicle count and metabolic profile being secondary outcomes. The primary analysis will follow the intention-to-treat principle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by the ethics committees of Zhongshan Hospital, Fudan University and all participating centres. All participants will provide written informed consent before randomisation. The results will be published in a peer-reviewed journal and will be presented at international meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT06842524\">NCT06842524<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-108980","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:45:42Z","timestamp":1781873142000},"page":"e108980","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Dihydroartemisinin for the treatment of polycystic ovary syndrome: study protocol for a multi-centre placebo-controlled randomised clinical trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06842524","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"Liangshan","family":"Mu","sequence":"first","affiliation":[{"name":"Reproductive Medicine Centre, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5480-6164","authenticated-orcid":false,"given":"Yanting","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiquan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Women and Children\u2019s Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8063-7906","authenticated-orcid":false,"given":"Changqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Centre, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-0909","authenticated-orcid":false,"given":"Wentao","family":"Li","sequence":"additional","affiliation":[{"name":"National Perinatal Epidemiology and Statistics Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8337-550X","authenticated-orcid":false,"given":"Ben Willem","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Dong","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Centre, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Zhongshan Hospital Fudan University, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"2026090306271767000_16.6.e108980.1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463"},{"key":"2026090306271767000_16.6.e108980.2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2015-1018"},{"key":"2026090306271767000_16.6.e108980.3","doi-asserted-by":"publisher","DOI":"10.1210\/er.2015-1104"},{"key":"2026090306271767000_16.6.e108980.4","doi-asserted-by":"crossref","unstructured":"Kempegowda P , Melson E , Manolopoulos KN , et al . Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab 2020;11. doi:10.1177\/2042018820934319","DOI":"10.1177\/2042018820934319"},{"key":"2026090306271767000_16.6.e108980.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0666-1"},{"key":"2026090306271767000_16.6.e108980.6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa839"},{"key":"2026090306271767000_16.6.e108980.7","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0013"},{"key":"2026090306271767000_16.6.e108980.8","doi-asserted-by":"publisher","DOI":"10.1210\/me.13.6.946"},{"key":"2026090306271767000_16.6.e108980.9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.12.5925"},{"key":"2026090306271767000_16.6.e108980.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048963","article-title":"Cholesterol side-chain cleavage gene expression in theca cells: augmented transcriptional regulation and mRNA stability in polycystic ovary syndrome","volume":"7","author":"Wickenheisser","year":"2012","journal-title":"PLoS One"},{"key":"2026090306271767000_16.6.e108980.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.01.003"},{"key":"2026090306271767000_16.6.e108980.12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2471"},{"key":"2026090306271767000_16.6.e108980.13","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.108"},{"key":"2026090306271767000_16.6.e108980.14","doi-asserted-by":"crossref","unstructured":"Liu Y , Jiang J , Du S , et al . Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction. Science 2024;384. doi:10.1126\/science.adk5382","DOI":"10.1126\/science.adk5382"},{"key":"2026090306271767000_16.6.e108980.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1523236113"},{"key":"2026090306271767000_16.6.e108980.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0509-0"},{"key":"2026090306271767000_16.6.e108980.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00456-z"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-108980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:28:17Z","timestamp":1788442097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-108980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,19]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjopen-2025-108980"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-108980","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}